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Introduction
　Cardiovascular disease（CVD）is the most common cause of morbidity and mortality 
among patients on hemodialysis（HD）.  Several risk factors, including aging, hypertension, 
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Abstract : Cardiovascular disease（CVD）is the most common cause of morbid-
ity and mortality among patients on hemodialysis（HD）.  Increasing evidence 
suggests that paraoxonase（PON）1 is an important risk factor for CVD.  In 
this study, we evaluated the correlations between PON1 protein concentration 
and cardiac function and atherosclerosis in patients on HD.  A cohort of 119 
patients（59 males）on maintenance HD participated in the study in which we 
measured common clinical parameters and serum PON1 concentrations.  We 
also evaluated cardiac function by echocardiography after maintenance dialysis 
sessions.  The median serum PON1 concentration was 40.8μg / mL（range, 
11.8-81.1μg / mL）in patients on HD and is significantly associated with a 
history of CVD and peripheral artery disease.  The serum PON1 level is posi-
tively correlated with the concentration of albumin（r＝0.26, P＜0.01）, high-
density lipoprotein cholesterol（HDL, r＝0.19, P＜0.05）, calcium（r＝0.23, P
＜0.05）, urea nitrogen（r＝0.20, P＜0.05）and creatinine（r＝0.22, P＜0.05）, 
and negatively correlated with pulse pressure（r＝-0.20, P＜0.05）.  Among 
the echocardiographic parameters, the PON1 concentration is signicantly and 
negatively correlated with left atrial dimension（LAD, r＝-0.31, P＜0.05）and 
left ventricular mass index（LVMI, r＝-0.35, P＜0.005）.  Stepwise multivariate 
regression analysis showed that PON1 is an independent predictor of LVMI
（adjusted r2＝0.34）.  Therefore the serum PON1 concentration could contrib-
ute to the development of LVH and it could be an independent predictor of 
CVD in patients on maintenance HD.
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inflammation, malnutrition and dyslipidemia, are associated with the accelerated develop-
ment of atherosclerosis.  The prevalence of dyslipidemia is approximately 67％ in patients 
on dialysis 1）, and it is characterized by reduced high-density lipoprotein cholesterol（HDL）
and modestly increased triglyceride, but not by increased low-density lipoprotein cholesterol
（LDL）2）.  Epidemiological studies have demonstrated an inverse correlation between plasma 
levels of HDL and the risk of CVD among patients with chronic renal failure.  Not only 
is HDL a key player in reverse cholesterol transport, but it also protects LDL against 
oxidation.  The essential mechanism of the inhibition of LDL oxidation by HDL is partly 
enzymatic, and paraoxonase 1（PON1）has been implicated in this process3, 4）.
　Human serum PON1（aryldialkylphosphatase, EC 3.1.8.1）is a calcium-dependent esterase 
associated with apolipoprotein A1 in HDL.  PON1 hydrolyzes organophosphates（e.g., 
paraoxon, diazoxon）and arylesters（e.g., phenylacetate）, and it also possesses antioxidative 
activity 4）.  PON1 hydrolyzes phospholipid peroxides in both HDL and LDL in vitro, and 
through this activity HDL prevents the oxidative modication of LDL4）.  Polymorphisms in 
PON1 at amino acid 55 that produces a leucine（L）to methionine（M）transition（L55M）, 
and at position 192 that produces a glutamine（Q）to arginine transition（Q192R）inuence 
PON activity 5）.  The arylesterase activity of PON1 is not polymorphic6）.
　Serum PON1 activity is low in patients with myocardial infarction 7）, hypercholesterolemia, 
diabetes mellitus8） and those on HD9, 10）, and PON1 has recently been considered a risk fac-
tor for coronary heart disease（CHD）.  Kujiraoka et al reported that Japanese patients with 
CHD had significantly lower serum PON1 concentrations than healthy controls, and this 
association was independent of the polymorphism at position 1926）.  These ndings indicate 
that PON1 plays an important role in CVD not only among healthy individuals, but also 
among patients with diabetes and chronic kidney disease（CKD）.  The association between 
PON1 and cardiac function, however, is not fully understood, particularly in patients with 
HD.
　The concentration of PON in serum has a strong and positive association with both 
serum arylesterase activity and serum paraoxonase activity 6）.  The present study used an 
enzyme-linked immunosorbent assay（ELISA）to investigate the correlation between serum 
PON1 concentration and both cardiac function and CVD risk factors in patients with HD.
Patients and Methods
Study Design and Subjects
　Stable patients on maintenance HD were solicited to participate in this study.  Only those 
patients who had been on regular dialysis three times each week for 3–4 h for at least three 
months were selected.  The exclusion criteria were as follows : current smokers, presence of 
acute or chronic liver disease, onset of cardiovascular disease during the previous six months, 
presence of overt infectious complications, statin administration and unwillingness to partici-
pate in the study.  Using these criteria, a cohort of 119 patients（59 males ; median age, 68 
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years）undergoing maintenance HD（median duration of HD, 64 months ; range, three – 368 
months）were enrolled.  The Showa University Medical Faculty Ethics Committee approved 
the study, and written informed consent was obtained from all of the participants.
　The causes of CKD were diabetic nephropathy in 35 patients（29％）, glomerulonephritis 
in 16 patients（13％）, polycystic kidney disease in ve patients（4％）, nephrosclerosis in 15 
patients（13％）, other causes in eight patients（7％）, and unknown causes in 40 patients
（34％）.  Fifty patients（42％）had a history of cerebrovascular, cardiovascular, and / or 
peripheral arterial disease（PAD）at the start of the study.  Twenty-four patients had PAD
（14 patients at Fontaine stage II-IV）, 11 patients had a history of stroke or cerebral bleed-
ing, and three patients had a history of aortic aneurysms.
　Erythropoietin was administered to 102（88％）of the patients.  Most of the patients 
were undergoing double or triple therapy, including angiotensin-converting enzyme inhibitors
（ACEI, 11％）or angiotensin receptor blockers（ARB, 24％）, calcium channel blockers, and /
or β-blockers in various combinations, as well as other drugs that are generally used to 
treat CKD, such as phosphate, potassium binders and diuretics.
Samples and Laboratory Methods
　Venous blood was collected from the arteriovenous fistula of each patient into one 
EDTA-containing tube and one serum sample tube before the rst dialysis session of the 
week.  Samples were immediately centrifuged at 1500×g for 10 min at 4℃ and stored fro-
zen at -70℃ if not analyzed immediately.  Serum / blood levels of leukocytes, hemoglobin, 
platelets, albumin, urea nitrogen, creatinine, uric acid, calcium, phosphorus, intact parathyroid 
hormone（PTH）, cholesterol, triglyceride, HDL, LDL, blood sugar, C-reactive protein and 
brain natriuretic peptide（BNP）were determined using routine methods at a clinical labora-
tory.
Sandwich ELISA for Determination of Serum PON Concentration
　Microtiter plate wells were coated with 0.25μg of the monoclonal antibody, 5-10D, and 
were incubated at 4℃ overnight.  Non-specific binding was blocked with Block AceTM
（Dainihon Pharmacy, Osaka, Japan）for 2 h at room temperature.  Standard and serum sam-
ples［diluted in PBS containing 0.1％ 3-［（3-cholamidopropyl）dimethylammonio］-propanesulfo-
nic acid（CHAPS）］were added to the wells, and the plates were incubated for 2 h at room 
temperature.  The plates were washed with PBS containing 0.1％ Tween 20, whereupon 100 
μL of biotinylated monoclonal antibody 4C-1（0.5μg / mL）was added to each well and 
they were incubated for 2 h at room temperature.  The plates were similarly washed again 
and 100μL of avidin-horseradish peroxidase conjugate（0.2μg / mL）in PBS containing 
0.1％ Tween 20 was added to the wells.  After incubation for 1 h at room temperature,  the 
plates were washed and 100μL of o-phenylenediamine dihydrochloride（0.4 mg）in 50 mM 
citrate buffer（pH 5.0）containing 0.012％ H2O2, was added to each well and the plates 
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were incubated for 30 min at room temperature.  The reaction was terminated by the addi-
tion of 20μL of 1 M H2SO4, and absorbance was determined at 492 nm using a microplate 
reader.  Serum concentrations of PON were determined by reference to a standard curve 
constructed with puried PON6）.
　We compared the PON concentration and arylesterase activity that had been previously 
determined11） and established that the PON concentration can be used as marker for PON 
hydrolytic activity in dialysis patients.  The PON concentration was strongly associated with 
arylesterase activity in HD patients（Fig. 1）.
Echocardiography
　Ultrasonographic scans of cardiac function were evaluated with high-resolution echo color 
Doppler ultrasonography, SSA370A（Toshiba Medical Systems, Tokyo, Japan）after dialysis 
sessions.  The same physician examined all of the patients by two-dimensional M-mode 
pulsed-wave and color Doppler sonography.
Statistical Analysis
　All values are shown as medians and ranges unless indicated otherwise.  A P value of ＜
0.05 was considered statistically signicant.  Comparisons between two groups were assessed 
using the Wilcoxon rank-sum and Fisher’s exact tests for continuous and nominal variables, 
respectively.  Correlations between the PON1 concentration and other variables were 
determined using Spearman’s rank correlation.  The multivariate stepwise regression analysis 
for the left ventricular mass index（LVMI）employed a model that included the following 
parameters : age, gender, history of CVD, diabetes, hemoglobin, albumin, creatinine, C-reactive 
protein, LDL and PON1 concentration.  All data were statistically analyzed using JMP, ver-
sion 7.0.1 for Macintosh（SAS Institute Inc., Cary, NC, USA）.
Fig. 1.　Association between PON1 concentration 
and arylesterase activity in dialysis patients
（adjusted r2＝0.83, p＜0.0001）
203Paraoxonase1 and LVMI in Hemodialysis
Results
　The median serum PON1 concentration was 40.8μg / mL（range, 11.8 – 81.1μg / mL）in 
patients with HD.  Table 1 shows associations between patients’ characteristics and serum 
PON1 levels.  The PON1 concentration is signicantly lower in patients with a history of 
CVD（P＜0.05）.  The PON1 concentration is also signicantly lower in patients on HD 
who also had peripheral artery disease（PAD）compared with those without PAD（P＜
0.005）.  Serum PON1 concentration did not signicantly differ with gender, diabetes, and the 
use of erythropoietin, ACEIs, ARBs and phosphate binders.
　Table 2 shows associations between PON1 concentrations and laboratory parameters in 
patients with HD.  Serum PON1 levels are positively correlated with albumin（r＝0.26, P＜
0.01）, HDL（r＝0.19, P＜0.05）, calcium（r＝0.23, P＜0.05）, urea nitrogen（r＝0.20, P＜
0.05）and creatinine（r＝0.22, P＜0.05）, but negatively correlated with pulse pressure（r＝
-0.20, P＜0.05）.  The PON1 concentration was not associated with age, body mass index, 
leukocyte, hemoglobin, platelets, total cholesterol, triglyceride, LDL, phosphorus, C-reactive 
protein, intact PTH and BNP.
　Table 3 shows the association between the PON1 concentration and echocardiographic 
parameters in patients on HD.  These data indicate that the PON1 concentration is signi-
cantly and negatively correlated with left atrial dimension（LAD, r＝-0.31, P＜0.05）and 
LVMI（r＝-0.35, P＜0.005, Fig. 2）.  We detected a trend towards negative correlations 
between PON1 and left ventricular diameter at end diastole（LVDd）and left ventricular 
diameter at end systole（LVDs）, but the differences did not reach signicance（P＝0.05）. 
In addition, PON1 was not related to cardiac output（CO）and left ventricular ejection frac-
tion（LVEF）.
　We established the factors that were independently associated with LVMI in patients on 
dialysis using stepwise multivariate regression analysis（Table 4）.  This model explained the 
34％ variation in the LVMI of this population.  Our results show that PON1 is one of the 




（μg / mL） p value
Gender（Male / Female） 59 / 60 39.6 / 41.2 0.9
CVD（yes / no） 50 / 69 38.9 / 42.8 ＜0.05
Diabetes（yes / no） 35 / 84 41.3 / 39.7 0.4
Peripheral artery disease（yes / no） 24 / 95 36.0 / 42.0 ＜0.005
Erythropoietin（yes / no） 102 / 16 39.9 / 44.2 0.8
ACEIs or ARBs（yes / no） 39 / 78 39.6 / 41.9 0.4
Phosphate binder（yes / no） 78 / 39 41.7 / 38.0 0.3
All values are shown as medians.
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most important independent predictors of LVMI（β＝-0.34）.
Discussion
　Left ventricular hypertrophy（LVH）is associated with high mortality rates in the general 
Table 2.　Spearman rank correlation coefcients for serum PON1 concentrations relative to 
variables in patients on HD.
Median（range） Spearman rho p value
Age（years）  68 （30-93） -0.14 0.1
Body Mass Index  20.3 （12.3-30.0） -0.02 0.8
Systolic blood pressure（mmHg）  140 （90-187） -0.09 0.38
Diastolic blood pressure（mmHg）  80 （55-109） -0.046 0.63
Pulse pressure（mmHg）  60 （20-100） -0.20 ＜0.05
Leukocytes（×103 / mm3）  5.3 （2.0-11.8） -0.06 0.5
Hemoglobin（g / dL）  9.7 （7.2-12.5） -0.05 0.6
Platelets（×104 /μL）  17.7 （5.6-34.5） 0.09 0.2
Albumin（g / dL）  3.9 （3.1-4.7） 0.26 ＜0.01
Total cholesterol（mg / dL）  157 （91-279） 0.1 0.2
Triglyceride（mg / dL）  95 （29-489） -0.05 0.6
HDL cholesterol（mg / dL）  45 （9-105） 0.19 ＜0.05
LDL cholesterol（mg / dL）  84 （45-162） 0.06 0.5
Calcium（mg / dL）  9.4 （7.6-11.0） 0.23 ＜0.05
Phosphorus（mg / dL）  5.6 （2.6-8.4） -0.07 0.5
C-reactive protein（mg / dL）  0.08 （0.007-7.04） -0.17 0.06
Urea nitrogen（mg / dL）  73.8 （38-119.5） 0.20 ＜0.05
Creatinine（mg / dL）  10.8 （3.1-23.3） 0.22 ＜0.05
Intact parathyroid hormone（pg / dL）  120 （5-650） 0.002 0.9
Blood sugar（mg / dL）  120 （72-326） -0.14 0.2
Brain natriuretic peptide（BNP）（pg / dL）  167 （10-1273） -0.14 0.3
Table 3.　Spearman rank correlation coefcients for PON1 con-
centrations relative to echocardiographic parameters in 
patients on HD
Median（range） Spearman rho p value
CO（L / min）  4.6 （2.2-8.8） -0.17 0.2
LVEF  0.64 （0.34-0.94） 0.12 0.3
LAD（mm）  32 （16-52） -0.31 ＜0.05
LVDd（mm）  46 （31-63） -0.23 0.05
LVDs（mm）  30 （19-50） -0.24 0.05
LVMI（g / m2）  119 （53-252） -0.35 ＜0.005
CO, cardiac output ; LVEF, left ventricular ejection fraction ; LAD, 
left atrial dimension ; LVDd, left ventricular diameter at end 
diastole ; LVDs, left ventricular diameter at end systole ; LVMI, 
left ventricular mass index.
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population12）.  Patients with LVH frequently develop coronary artery disease, heart failure, 
stroke and other cardiovascular complications 13）.  Cardiac structural abnormalities such as 
LVH cannot be accounted for by hemodynamic factors alone.  Despite growing awareness 
of the need to clinically identify individuals with LVH for cardiovascular risk stratication, 
the pathophysiological basis of left ventricular structural and functional abnormalities in 
patients with hypertension remains unclear.  One important contributor to the pathogenesis 
of cardiovascular disease is oxidative stress.  In patients starting dialysis, LVH is the most 
common cardiac anomaly（75％ of patients）14）, and it is a powerful predictor of cardiovas-
cular outcomes among patients on HD15）.  Although LVH is likely to be a multifactorial 
process in CKD with a number of causes including anemia, pressure loading through 
hypertension and reduced vascular compliance, its mechanisms and suitable markers remain 
uncertain.  The present study shows that the serum concentration of PON1 is signicantly 
Fig. 2. Relationship between serum PON1 and 
LVMI in patients on HD（adjusted r2＝-
0.35, p＜0.005）.
Table 4.　Stepwise multivariate regression models of predictors of LVMI
Estimate Standard error β p value
Intercept 253.1 50.8 ＜0.0001
PON1 -1.3 0.4 -0.34 ＜0.005
History of CVD 8.2 4.1 0.21 ＜0.05
Hemoglobin -13.4 5.0 -0.28 ＜0.01
Creatinine 4.4 1.4 0.32 ＜0.005
C-reactive protein 22.2 10.7 0.22 ＜0.05
Multivariate stepwise regression analysis employed a model that included 
the following parameters : Age, gender, history of CVD, diabetes, hemo-
globin, albumin, creatinine, C-reactive protein, LDL, HDL and PON1. 
Adjusted r2＝0.34.
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associated with LVMI in patients on HD.  PON and arylesterase activity decreases in 
patients on HD independent of the L55M and Q192R PON1 gene polymorphisms16, 17）, and 
the human serum PON1 concentration predicts cardiovascular mortality in these patients18）. 
Oxidative stress markers, especially oxidized LDL, are associated with echocardiographic 
parameters such as LVMI and EF19）, therefore the serum PON1 concentration might predict 
the development of LVH in such patients.  This study is the rst to identify correlations 
between PON1 and LVH in patients on HD.
　Early epidemiological studies have recognized that a decrease in HDL, which is a com-
mon feature of type 2 diabetes mellitus and metabolic syndrome, is an independent predic-
tor of cardiovascular disease.  The benecial effects of HDL on the cardiovascular system 
have been attributed to its anti-inammatory, antioxidant and antithrombotic properties as 
well as its ability to reverse cholesterol transport.  These properties of HDL act together 
to improve endothelial function and to prevent atherosclerosis.  This study found that the 
serum concentration of PON1 is correlated with that of HDL, essentially because HDL is 
a carrier for PON1, which provides one explanation for the decreased PON1 concentration 
that is associated with changes in HDL concentrations.  This association may provide one 
explanation for the accelerated CVD in patients on dialysis.  A relationship between LVH 
and HDL has been established in both hypertensive patients and in the general popula-
tion20）.  HDL is an independent predictor of LVH among Japanese patients with essential 
hypertension, and it is inversely related to the risk of cardiovascular events.  There is a 
negative relationship between HDL levels and LVMI21）.  These studies suggest that HDL 
has direct cardioprotective effects and since paraoxonase is a central contributor to the anti-
oxidant capacity of HDL, this provides an explanation for the association of serum PON1 
concentration with LVMI in patients on HD.
　Multivariate analysis revealed that the serum PON1 concentration is signicantly correlated 
with LVMI after adjusting for the HDL concentration.  Impaired HDL metabolism, such as 
a reduction in the HDL2 subfraction and a decreased ratio of HDL2 to HDL3 cholesterol, 
has been recognized in patients who are on dialysis and in uremic patients22）.  The HDL 
concentration might also be regulated independently by its constituent fractions other than 
PON1.  Hence, HDL might be qualitatively and quantitatively changed in patients on dialy-
sis.  The role of HDL in CVD complications remains to be determined and this may be 
difcult because HDL is multifunctional, especially in patients on dialysis.  We propose that 
PON1 is associated with the cardioprotective function of HDL.  Although hypertension is a 
leading risk factor for LVH, the systolic pressure prior to dialysis represents no more than 
16％ of the variance in LV mass among patients with ESRD23）.  Thus, the high prognostic 
value of LVH in patients with CKD must depend on the fact that LV mass integrates not 
only the long-term effects of hypertension, but also the combined effect of other risk factors. 
Our ndings suggest that PON1 has direct cardioprotective effects in patients on dialysis.
　Several mechanisms have been proposed to explain the role of low PON1 activity in 
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causing LVH.  One possible effect of PON1 on LVMI might be the direct inhibition of 
oxidative stress and inammation.  Free radicals, especially of the superoxide family, increase 
during the development of pressure-overload myocardial hypertrophy24）.  Reactive oxygen 
species（ROS）can induce myocardial contractile dysfunction and structural damage25）. 
Moreover, inammation is an independent risk factor for high blood pressure and therefore 
inammatory cytokines could be associated with LVH26）.  Oxidative stress and inamma-
tion promotes several key events in the development of cardiovascular disease.  Complexes 
of PON1 with HDL are implicated in the anti-inammatory and antioxidant activities of 
HDL27） and genetic polymorphisms of PON1 are associated with systemic oxidative stress 
and cardiovascular risk 28）.  Thus, the association between LVH and PON1 could be related 
to its antioxidant and anti-inammatory effects, but in this study, we found that the serum 
PON1 level did not correlate with C-reactive protein（r＝-0.17, P＝0.06）.
　Several limitations of this study need to be considered, including the fact that there was 
not a control group, and the sample size was relatively small.  In addition, our ndings 
cannot explain the mechanisms of the cardioprotective effect of PON1 due to the cross-
sectional design of the study.  A further limitation was that the patients’ registrations were 
obtained from only two dialysis facilities.  Treatment with ACEIs and ARBs can inuence 
lipid proles and oxidative stress, but these parameters were not affected in patients who 
were taking these drugs.  We dened atherosclerosis based only on a history of CVD and 
echocardiographic parameters.
Conclusions
　In summary, our ndings indicate that the serum PON1 concentration could contribute to 
the development of LVH and could be an independent predictor of CVD in patients on 
maintenance HD.  In addition, a decrease in PON1 might be one cause of atherosclerotic 
progression in patients on HD.  Prospective long-term follow up studies should clarify the 
inuence of PON1 and cardiovascular morbidity and mortality among patients on HD.
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